AFI-002 is under clinical development by Altus Formulation and currently in Phase III for Attention Deficit Hyperactivity Disorder (ADHD). According to GlobalData, Phase III drugs for Attention Deficit Hyperactivity Disorder (ADHD) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AFI-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AFI-002 is under development for the treatment of attention deficit hyperactivity disorder (ADHD). The drug candidate is a abuse deterrent extended release tablet formulation which is bio-equivalent to a leading ADHD medication. It is administered orally. It is developed based on Intellitab technology.
Altus Formulation overview
Altus Formulation is a drug development company which designs and develops medicines to treat chronic pains. It is investigating AFI-001, AFI-003 and AFI-004 against severe pain; AFI-002 to treat ADHD (attention deficit hyperactivity disorder); AFI-005 targeting severe acute pain; PPI-1501 and PPI-1502 to treat postoperative pain. The company is also evaluating AcetaFlex, an extended release formulation of acetaminophen (paracetamol) against mild to moderate pain; and TramaFlex to treat moderate to severe pain. The company utilizes SmartCelle technology platform to deliver insoluble drugs; INTELLITAB and FLEXITAB technologies to develop its products. Altus Formulation is headquartered in Montreal, Quebec, Canada.
For a complete picture of AFI-002’s drug-specific PTSR and LoA scores, buy the report here.